Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from RBC Capital Markets

FTSE 100’s early promise fades as Bank of England holds rates

The FTSE 100 Index closed down 11.14 points at 10,897.27.

Evening Standard

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio. Speaking at RBC Capital Markets’ 20

MarketBeat

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets’ 2026

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch

MarketBeat

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

MarketBeat

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis’ guidance

MarketBeat

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capi

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-free survival data for the company’s highlighted cervical and head and neck canc

MarketBeat

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones. The discussio

MarketBeat

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf

MarketBeat

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo

MarketBeat

FTSE 100 flat as AB Foods and Tesco disappoint

The FTSE 100 index closed down 3.52 points at 10,044.69.

Evening Standard

Trump’s strike on Venezuela gives the U.S. 30% of the world’s oil reserves on paper and a $100 billion rebuilding job in reality

“I don't think any large U.S. major company is going to want to invest without a series of guarantees,” one historian of Venezuela said.

Fortune

MongoDB Stock Soars, 9 Analysts Hike Estimates After Blockbuster Results

MongoDB Inc (NASDAQ:MDB) shares climbed in early trading on Tuesday after the company reported upbeat fiscal third-quarter results.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FTSE 100 ends flat as bank gains offset weak gold

Elsewhere, UK lenders passed the latest Bank of England stress tests.

Benzinga

Autodesk's Strong Quarter Validates Analyst Optimism As Infrastructure, AI Drive Gains

Autodesk, Inc (NASDAQ:ADSK) posted a strong third quarter with double-digit revenue and billings growth, expanded profitability, and a higher full-year outlook as demand for its Architecture, Engineering, and Construction (AEC) and cloud-based design tools continues to surge.

Benzinga

Zscaler Posts Q1 Beat, Red Canary Contribution Disappoints Investors

Shares of Zscaler Inc (NASDAQ:ZS) tanked in early trading on Wednesday, even after the company reported upbeat fiscal first-quarter earnings.

Benzinga

Workday Posts Q3 Beat, Analysts Cut Price Targets On Outlook

Shares of Workday Inc (NASDAQ:WDAY) tanked in early trading on Wednesday, even after the company reported upbeat third-quarter earnings.

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Stocks fall amid weak GDP print ahead of Budget

The FTSE 100 index closed down 103.74 points, 1.1%, at 9,807.68.

Benzinga

ADP Q1 Preview: Sustained Revenue Growth, Improved Bookings Momentum

Automatic Data Processing Inc (NASDAQ:ADP) is likely to have sustained the previous quarter's 7.5% year-on-year revenue growth, while its booking momentum could have improved, according to RBC Capital Markets.

Benzinga

Moody's To Benefit From M&A Activity Recovery, Margins Expansion, Analysts Say

Moody’s Corp (NYSE:MCO) reported solid third-quarter results on Wednesday.

Benzinga

Micron Technology Smashes Q4 Estimates, Pricing Drives GM Outlook; Analysts Raise Price Target

Shares of Micron Technology Inc (NASDAQ:MU) dipped in early trading on Wednesday despite a strong fiscal fourth quarter report.

Benzinga

Adobe Beats Expectations As Analysts Weigh Strong AI Growth Against Market Risks

As technology companies navigate the rapidly evolving landscape of artificial intelligence, industry giants are increasingly under pressure to demonstrate robust financial performance and strategic innovation. This backdrop of heightened competition and technological advancement sets the stage for Adobe Inc.‘s (NASDAQ:ADBE) latest financial results, which have captured the attention of analysts and…

Benzinga

Figma Analysts Highlight Record Quarter, But Market Focuses On Margins And Growth

Can a record revenue quarter still be considered a setback? As Figma Inc.‘s (NYSE:FIG) shares plummet and analysts scramble to adjust their forecasts, the surprising details behind the numbers reveal why the market isn’t impressed.

Benzinga

Google Stock Roars Back After 'Government Folds Like Cheap Suit'

Wall Street's sentiment on Alphabet, Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) has turned sharply positive following Tuesday's long-anticipated ruling in the DOJ search antitrust case, with the decision largely favoring the company relative to investor expectations.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.